Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
USA 122 , e2404899122 (2025)
Discussion This observational cohort study describes real-world utilization patterns and characteristics of patients dispensed an SGLT2i or GLP-1 RA in the US using data from Optum CDM in the period following changes to the landscape for treatment and prevention of CKD in type 2 diabetes (later period, July 2021September 2023) as well as temporal changes in utilization and baseline characteristics relative to the period prior (earlier period, January 2012June 2021)
We recommend pairing TruFlex with a regular workout routine
Patients report better control over blood sugar levels, reduced blood pressure, improved cholesterol profiles, and decreased markers of inflammation
The 503B designation gives Olympia similar batch manufacturing capabilities to Empower
Self-administration preference
